Literature DB >> 24626526

Decreased PPAR-γ expression in the conjunctiva and increased expression of TNF-α and IL-1β in the conjunctiva and tear fluid of dry eye mice.

Yihui Chen1, Xiaoyan Zhang2, Ling Yang3, Min Li1, Bing Li1, Weifang Wang1, Minjie Sheng1.   

Abstract

The aim of this study was to investigate the expression of peroxisome proliferator-activated receptor γ (PPAR-γ), tumor necrosis factor (TNF)-α and interleukin (IL)-1β in the conjunctiva and the association between inflammatory cytokines and PPAR-γ in dry eye mice. Dry eye was induced in 6-week-old female C57 mice. mRNA expression of PPAR-γ, TNF-α and IL-1β were measured. PPAR-γ protein expression in the conjunctiva, and the contents of TNF-α and IL-1β in the conjunctiva and tear-wash fluid were determined. A PPAR-γ agonist, pioglitazone (PIO), was used to treat dry eye mice. Dry eye mice presented with similar manifestations as in humans. The PPAR-γ expression in the conjunctiva of dry eye mice was downregulated, accompanied by increased contents of TNF-α and IL-1β. PIO treatment markedly reduced the contents of TNF-α and IL-1β in tear fluid of dry eye mice. Following PIO treatment, the PPAR-γ expression increased markedly. PIO may activate PPAR-γ to inhibit the expression of the inflammatory cytokines TNF-α and IL-1β in dry eye mice. This suppresses the inflammatory progression, increases the tear fluid production, elevates the tear film stability and reduces the damage to the ocular surface, exerting a therapeutic effect on dry eye.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24626526     DOI: 10.3892/mmr.2014.2041

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  12 in total

1.  Effects of carvedilol reduce conjunctivitis through changes in inflammation, NGF and VEGF levels in a rat model.

Authors:  Ying Chen; Xianfei Hong
Journal:  Exp Ther Med       Date:  2016-03-10       Impact factor: 2.447

Review 2.  Immune - Goblet cell interaction in the conjunctiva.

Authors:  Jehan Alam; Cintia S de Paiva; Stephen C Pflugfelder
Journal:  Ocul Surf       Date:  2020-01-14       Impact factor: 5.033

Review 3.  The role of peroxisome proliferator-activated receptors in healthy and diseased eyes.

Authors:  Paulina Escandon; Brenda Vasini; Amy E Whelchel; Sarah E Nicholas; H Greg Matlock; Jian-Xing Ma; Dimitrios Karamichos
Journal:  Exp Eye Res       Date:  2021-05-16       Impact factor: 3.770

Review 4.  Role of Peroxisome Proliferator-Activated Receptor γ in Ocular Diseases.

Authors:  Su Zhang; Hongwei Gu; Nan Hu
Journal:  J Ophthalmol       Date:  2015-06-04       Impact factor: 1.909

5.  The Effect of TNF-α Blocker HL036337 and Its Best Concentration to Inhibit Dry Eye Inflammation.

Authors:  Wungrak Choi; Hyemi Noh; Areum Yeo; Hanmil Jang; Hyea Kyung Ahn; Yeon Jung Song; Hyung Keun Lee
Journal:  Korean J Ophthalmol       Date:  2016-07-21

6.  Involvement of adiponectin in age-related increases in tear production in mice.

Authors:  Yosuke Shikama; Mie Kurosawa; Masae Furukawa; Naozumi Ishimaru; Kenji Matsushita
Journal:  Aging (Albany NY)       Date:  2019-10-08       Impact factor: 5.682

7.  Cluster Analysis of Dry Eye Disease Models Based on Immune Cell Parameters - New Insight Into Therapeutic Perspective.

Authors:  Chit Tong Lio; Sandeep Kumar Dhanda; Tanima Bose
Journal:  Front Immunol       Date:  2020-09-29       Impact factor: 7.561

8.  Chemokines Up-Regulated in Epithelial Cells Control Senescence-Associated T Cell Accumulation in Salivary Glands of Aged and Sjögren's Syndrome Model Mice.

Authors:  Mie Kurosawa; Yosuke Shikama; Masae Furukawa; Rieko Arakaki; Naozumi Ishimaru; Kenji Matsushita
Journal:  Int J Mol Sci       Date:  2021-02-25       Impact factor: 5.923

9.  Dexamethasone-Loaded Nanostructured Lipid Carriers for the Treatment of Dry Eye Disease.

Authors:  Sangeeta Kumari; Madhuri Dandamudi; Sweta Rani; Elke Behaeghel; Gautam Behl; David Kent; Niall J O'Reilly; Orla O'Donovan; Peter McLoughlin; Laurence Fitzhenry
Journal:  Pharmaceutics       Date:  2021-06-18       Impact factor: 6.321

10.  High-Mobility Group Box 1 in Dry Eye Inflammation.

Authors:  Carolina Lema; Rose Y Reins; Rachel L Redfern
Journal:  Invest Ophthalmol Vis Sci       Date:  2018-04-01       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.